Adalimumab Anti-TNF JIA, IBD infection, malignancy, arrhythmia, heart failure, HT, headache, rash, vomit, neutropenia, hepatic necrosis, allergic reaction Alemtuzumab Anti-CD52, multiple sclerosis, Extensive pancytopenia, infusion reaction, (Campath) expressed on acute GVHD lympholysis by fever, infection, malignancy, lymphocytes, apoptosis of autoimmune disease, headache, monocytes, targeted cells paraesthesia, vomit, rash, thyroid macrophages & disease, limb pain NK cells Anakinra IL-1 inhibitor JIA, KD, FMF, headache, rash, vomit, neonatal-onset thrombocytopenia, leukopenia, multisystem infection, allergic reaction inflammatory disease Basiliximab Anti-IL-2 receptor, Solid organ Prevent infection, arrhythmia, heart failure, anti-CD25 transplant mediated chest pain, hypertension, allograft hypotension, agitation, headache, rejection (IL-2 cytopenia, CRS, allergic reaction receptor is critical for rejection) Blinatumomab Anti-CD3/CD19 Engages T-cell Cytokine release syndrome, ALL, B cell activity by linking neurotoxicity (seizures, tremor, lymphoma CD3+ encephalopathy), liver toxicity cells with CD19+ cells. Resultant cytotoxic T cell engagement leads to target cell lysis Chimeric anti-CD19 (can be Engineered Cytokine release syndrome, antigen specified) ALL, CLL, B cell lymphocytes link neurotoxicity (seizure, receptor T cells lymphoma to CD19, encephalopathy, ischemic stroke) (CART) resultant cytotoxic T-cell engagement leads to target cell lysis
Adalimumab Anti-TNF JIA, IBD infection, malignancy, arrhythmia, heart failure, HT, headache, rash, vomit, neutropenia, hepatic necrosis, allergic reaction Alemtuzumab (Campath) Anti-CD52, expressed on lymphocytes, monocytes, macrophages & NK cells multiple sclerosis, acute GVHD Extensive lympholysis by apoptosis of targeted cells pancytopenia, infusion reaction, fever, infection, malignancy, autoimmune disease, headache, paraesthesia, vomit, rash, thyroid disease, limb pain Anakinra IL-1 inhibitor JIA, KD, FMF, neonatal-onset multisystem inflammatory disease headache, rash, vomit, thrombocytopenia, leukopenia, infection, allergic reaction Basiliximab Anti-IL-2 receptor, anti-CD25 Solid organ transplant Prevent allograft rejection (IL-2 receptor is critical for rejection) infection, arrhythmia, heart failure, chest pain, hypertension, hypotension, agitation, headache, cytopenia, CRS, allergic reaction Blinatumomab Anti-CD3/CD19 ALL, B cell lymphoma Engages T-cell activity by linking CD3+ cells with CD19+ cells. Resultant cytotoxic T cell engagement leads to target cell lysis Cytokine release syndrome, neurotoxicity (seizures, tremor, encephalopathy), liver toxicity Chimeric antigen receptor T cells (CART) anti-CD19 (can be specified) ALL, CLL, B cell lymphoma Engineered link to CD19, resultant cytotoxic T-cell engagement leads to target cell lysis Cytokine release syndrome, neurotoxicity (seizure, encephalopathy, ischemic stroke) lymphocytes mediated